Erratum: Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5 (Oncotarget (2017) 8 (31041-31056))



Al-Jameel, W, Gou, X, Forootan, SS, Al Fayi, MS, Rudland, PS ORCID: 0000-0002-7491-0846, Forootan, FS, Zhang, J, Cornford, PA ORCID: 0000-0002-7146-9258, Hussain, SA and Ke, Y ORCID: 0000-0001-5341-8644
(2020) Erratum: Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5 (Oncotarget (2017) 8 (31041-31056)). Oncotarget, 11 (31). 3025-.

[img] Text
024823R1.pdf - Published version

Download (11MB)

Abstract

This article has been corrected: The following references were accidentally omitted from the published list: 54. Xu M, Joo HJ, Paik YK. Novel functions of lipid-binding protein 5 in Caenorhabditis elegans fat metabolism. J Biol Chem. 2011; 286:28111-8. https://doi.org/10.1074/jbc.M111.227165. [PubMed] 55. Pavese J, Ogden IM, Bergan RC. An orthotopic murine model of human prostate cancer metastasis. J Vis Exp. 2013; e50873. https://doi.org/10.3791/50873. [PubMed] 56. Janik P, Briand P, Hartmann NR. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res. 1975; 35:3698-704. [PubMed] 57. Thumser AE, Storch J. Characterization of a BODIPY-labeled fluorescent fatty acid analogue. Binding to fatty acid-binding proteins, intracellular localization, and metabolism. Mol Cell Biochem. 2007; 299:67-73. https://doi.org/10.1007/s11010-005-9041-2. [PubMed]

Item Type: Article
Uncontrolled Keywords: Prostate Cancer, Cancer, Urologic Diseases, Aging, 5.1 Pharmaceuticals, 2 Aetiology, 5 Development of treatments and therapeutic interventions, 2.1 Biological and endogenous factors, Cancer, Animals, Antineoplastic Agents, Binding, Competitive, Cell Line, Tumor, Cell Movement, Cell Proliferation, Cell Survival, Cyclobutanes, Dicarboxylic Acids, Disease Models, Animal, Disease Progression, Drug Discovery, Drug Screening Assays, Antitumor, Fatty Acid-Binding Proteins, Fatty Acids, Humans, Ligands, Male, Mice, Neoplasm Metastasis, PPAR gamma, Prostatic Neoplasms, Castration-Resistant, Protein Binding, Xenograft Model Antitumor Assays
Depositing User: Symplectic Admin
Date Deposited: 06 Mar 2017 07:41
Last Modified: 14 Mar 2024 17:23
DOI: 10.18632/oncotarget.16055
URI: https://livrepository.liverpool.ac.uk/id/eprint/3006216